MREO on Nasdaq

Mereo BioPharma Group plc

We are a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases.4 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with Catabasis Pharmaceuticals, DiaMedica Therapeutics Inc. or EXICURE, INC., or pick any stock.

  • TickerMREO on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersLondon, United Kingdom2
  • Incorporated inUnited Kingdom3
  • Business addressOne Cavendish Place, Fourth Floor, London, W1G 0Qf3
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formPublic Limited Company2
  • LEI213800U8JQHIJOS5AS092
  • StatusActive2
  • LEI statusIssued and current2
  • Registered address4th Floor, One, W1G 0QF London, United Kingdom2
  • Registered withCompanies House, 094811612

See how the biggest companies compare on our leaderboards

We are a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. We have developed a portfolio of late-stage clinical product candidates. Our late-stage rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (“OI”) and alvelestat for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (“AATD-LD”). Setrusumab has received orphan designation for OI from the European Commission (“EC”) and the FDA, PRIME designation from the EMA and has Breakthrough Therapy designation and rare pediatric disease designation from the FDA. Alvelestat has received orphan designation for AATD from the EC and the FDA, and Fast Track designation for the treatment of AATD-LD from the FDA. We also have an early-stage rare disease program, vantictumab, for the treatment of a second bone disease, autosomal domina…4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-8021.4%Operating margin5
-8375.6%Net margin5
-102.4%Return on equity5
-$31.0MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development99¢$17.8M
  • Interest1¢$255.0K

Out of $500.0K in revenue.5 The company lost money this year.

Financial statements

Revenue6785$500.0K in 2025−99% since 2021
0$10.0M$20.0M$30.0M$40.0M2021: $36.5M$36.5M20212022: $0$020222023: $10.0M$10.0M20232024: $0$020242025: $500.0K$500.0K2025
Operating income96785-$40.1M in 2025+1% since 2019
-$60.0M-$40.0M-$20.0M02019: -$39.5M-$39.5M20192020: -$37.6M-$37.6M2020−5%2021: -$20.9M-$20.9M2021−44%2022: -$54.4M-$54.4M2022+160%2023: -$28.4M-$28.4M2023−48%2024: -$47.4M-$47.4M2024+67%2025: -$40.1M-$40.1M2025−15%
Net income785-$41.9M in 2025−1% since 2022
-$60.0M-$40.0M-$20.0M02022: -$42.2M-$42.2M20222023: -$29.5M-$29.5M2023−30%2024: -$43.3M-$43.3M2024+47%2025: -$41.9M-$41.9M2025−3%

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-12-312024-12-31
Revenue$500.0K$0
Cost of Revenue-$133.0K$0
Research and development-$17.8M-$20.9M
General and administrative-$23.0M-$26.4M
Other income$300.0K$0
Loss from operations-$40.1M-$47.4M
Interest income$2.2M$3.0M
Interest expense-$255.0K-$1.4M
Changes in the fair value of warrants$805.0K-$419.0K
Foreign currency transaction (loss)/gain, net-$6.3M$1.2M
Benefit from research and development tax credit$1.9M$1.6M
Net loss before income tax-$41.9M-$43.3M
Income tax benefit$0$0
Net loss-$41.9M-$43.3M
Loss per share - basic-$0.05-$0.06
Loss per share - diluted-$0.05-$0.06
Weighted average shares outstanding - basic797.1M shares739.6M shares
Weighted average shares outstanding - diluted797.1M shares739.6M shares
Other comprehensive income/(loss) - Foreign currency translation adjustments, net of tax$8.0M-$1.4M
Total comprehensive loss-$33.9M-$44.6M

Compare Mereo BioPharma Group plc with another company

Leadership

Who has led Mereo BioPharma Group plc, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Denise Pollard-Knight2024–now
2025
Board members and other officers (12)

Timeline

  1. Jan 2, 2024New chief executive Denise Pollard-Knight becomes CEO13
  2. Mar 10, 2015Founded Mereo BioPharma Group plc is founded2

Filings

280 filings to the SEC since October 2021: 5 annual reports, 8 quarterly reports, 27 major events, 80 insider forms, 65 large holders, 95 other. The latest 20:

  1. Aug 19, 20268-K EDGAR
  2. Aug 14, 2026SCHEDULE 13G/A EDGAR
  3. Aug 11, 202610-Q EDGAR
  4. Aug 11, 20268-K EDGAR
  5. Aug 11, 20268-K EDGAR
  6. May 15, 2026SCHEDULE 13G/A EDGAR
  7. May 14, 20268-K EDGAR
  8. May 14, 2026SCHEDULE 13G EDGAR
  9. May 12, 20268-K/A EDGAR
  10. May 12, 202610-Q EDGAR
  11. May 12, 20268-K EDGAR
  12. Apr 9, 2026ARS EDGAR
  13. Apr 9, 2026DEF 14A EDGAR
  14. Mar 27, 2026PRE 14A EDGAR
  15. Mar 27, 20268-K EDGAR
  16. Mar 19, 202610-K EDGAR
  17. Mar 19, 20268-K EDGAR
  18. Feb 27, 20264 EDGAR
  19. Feb 27, 20264 EDGAR
  20. Feb 27, 20264 EDGAR

The 280 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

22 open-market trades by officers, directors and large owners since October 2021: 0 buys and 22 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 13, 2024Scots-Knight DeniseChief Executive OfficerSale60,046$4.22$253.4KForm 4
Sep 13, 2024Lewicki John A.Chief Scientific OfficerSale10,937$4.22$46.2KForm 4
Sep 13, 2024Sermon CharlesGeneral CounselSale20,946$4.22$88.4KForm 4
Sep 13, 2024Fox Christine AnnChief Financial OfficerSale19,158$4.22$80.8KForm 4
Sep 13, 2024Hughes-Wilson AlexandraSee RemarksSale100,312$4.22$423.3KForm 4
Sep 12, 2024Scots-Knight DeniseChief Executive OfficerSale28,611$4.47$127.9KForm 4
Sep 12, 2024Lewicki John A.Chief Scientific OfficerSale5,212$4.47$23.3KForm 4
Sep 12, 2024Sermon CharlesGeneral CounselSale9,980$4.47$44.6KForm 4
Sep 12, 2024Fox Christine AnnChief Financial OfficerSale9,128$4.47$40.8KForm 4
Sep 12, 2024Hughes-Wilson AlexandraSee RemarksSale47,798$4.47$213.7KForm 4
Aug 22, 2024PAKIANATHAN DEEPIKADirectorSale105,244$4.43$466.2KForm 4
Jun 26, 2024Sermon CharlesGeneral CounselSale32,187$3.39$109.1KForm 4
Jun 26, 2024Lewicki John A.Chief Scientific OfficerSale16,808$3.39$57.0KForm 4
Jun 26, 2024Fox Christine AnnChief Financial OfficerSale29,439$3.39$99.8KForm 4
Jun 26, 2024Scots-Knight DeniseChief Executive OfficerSale92,273$3.39$312.8KForm 4
Jun 26, 2024Hughes-Wilson AlexandraSee RemarksSale22,968$3.39$77.9KForm 4
Jun 25, 2024Sermon CharlesGeneral CounselSale14,202$3.69$52.4KForm 4
Jun 25, 2024Lewicki John A.Chief Scientific OfficerSale7,416$3.69$27.4KForm 4
Jun 25, 2024Fox Christine AnnChief Financial OfficerSale12,990$3.69$47.9KForm 4
Jun 25, 2024Scots-Knight DeniseChief Executive OfficerSale40,712$3.69$150.2KForm 4

All 22 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 61. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Rubric Capital Management LP15,307,347$4.9M0.0%No change
683 Capital Management, LLC11,777,856$3.7M0.4%−222,144
Bank Of America Corp /de/8,195,281$2.6M0.0%−6
Defilade Capital Management, L.P.7,558,756$2.4M0.3%No change
Newtyn Management, LLC3,000,000$953.1K0.1%−4,079,056
Tejara Capital Ltd2,037,520$647.3K0.3%No change
UBS Group AG1,447,627$460.3K0.0%−42,501
Two Sigma Investments, LP1,319,241$419.1K0.0%+1,131,402
EcoR1 Capital, LLC1,000,000$317.7K0.0%−12,368,855
Jane Street Group, LLC774,944$246.2K0.0%+634,971
Ishara Investments LP768,750$244.2K0.2%New
Wealthspire Advisors, LLC765,000$243.0K0.0%−31,036
Citadel Advisors LLC444,158$141.1K0.0%New
Rangeley Capital, LLC329,200$104.6K0.1%No change
Susquehanna International Group, Llp213,270$67.8K0.0%+17,350
Marshall Wace, Llp179,884$57.6K0.0%−507,103
XTX Topco Ltd174,481$55.4K0.0%+90,012
Group One Trading LLC167,515$53.2K0.0%−168,312
State Street Corp134,772$42.8K0.0%+1,393
Nomura Holdings Inc104,361$33.2K0.0%New
James J. Burns & Company, LLC95,400$30.3K0.0%New
Quarry LP93,750$29.8K0.0%New
Goldman Sachs Group Inc85,180$27.1K0.0%New
JMN Financial LLC76,748$24.4K0.0%New
BlackRock, Inc.69,678$22.1K0.0%−233,313

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44